[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"non-obstructive-coronary-artery-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:non-obstructive-coronary-artery-disease":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,41],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100487970","imaging-coronary-microvascular-dysfunction-cmd-study-100487970",false,"NCT05634031","Imaging Coronary Microvascular Dysfunction (CMD) Study","Development and Validation of a Non-invasive Algorithm for Diagnosis of Microvascular Angina Among Patients With Ischemia and Non-obstructive Coronary Artery Disease (IMAGING-CMD Study)","Inclusion criteria:\n\n* Patients with symptoms of exertional angina and\u002For dyspnea (confirmed on Seattle Angina Questionnaire and Rose Dyspnea Questionnaire)\n* Evidence of non-obstructive CAD on CCTA or coronary angiography (no stenosis \\>50% and\u002For FFR if performed \\>0.80)\n\nExclusion criteria:\n\n* Patients with reduced LVEF (\\\u003C50%) or diagnosis of cardiomyopathy\n* Patients with co-existent moderate or severe valve disease\n* Patients with eGFR \\\u003C30 ml\u002Fmin\u002Fm2\n* History of prior coronary revascularization\n* Non-coronary indication for CCTA or coronary angiogram determining eligibility\n* Contraindications to regadenoson (severe asthma\u002Fchronic obstructive pulmonary disease, brady-arrhythmias, or systolic blood pressure \\\u003C90 mm Hg)\n* Inability to provide informed consent\n* Pregnancy","ALL","18 Years",{"count":19,"type":20},70,"ESTIMATED","INTERVENTIONAL",[23],"NA","Angina is a common clinical symptom of ischemic heart disease, affecting up to 11 million people in the United States alone, and 112 million people globally. Despite this, 4 in 10 patients undergoing elective coronary angiography for angina and ischemia do not have evidence of obstructive coronary artery disease (CAD). This condition of ischemia with no obstructive CAD (INOCA) is associated with high clinical and economic morbidity, as these patients have a higher rate of repeat procedures and hospitalizations, worse quality of life, future adverse cardiovascular events and frequent time missed from work.\n\nThe overall objective of this study is to develop and validate a non-invasive algorithm for diagnosis and management of patients with INOCA and suspected microvascular dysfunction centered around cardiac PET MPI. A secondary goal of the study is to assess for improvement in patient symptoms, function and quality of life from PET-guided management of CMD in patients with INOCA.\n\nThis study will take place at Mount Sinai Morningside in the PET and CTunit on the 3rd floor. The sub-study will occur at Mount Sinai Morningside Cath Lab on the 3rd floor. The study will enroll an estimated total of 70 subjects, 12 of which will also participate in the sub-study. The study is estimated to last 2 years.",[26,27],"Angina","Non-obstructive Coronary Artery Disease","RECRUITING","2025-04-11",{"date":31,"type":32},"2025-04-16","ACTUAL",{"date":34,"type":32},"2023-04-26",{"date":36,"type":20},"2027-03-01",{"name":38,"class":39},"Icahn School of Medicine at Mount Sinai","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":48,"minAge":17,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":21,"phases":51,"briefSummary":53,"conditions":54,"keywords":57,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":40},"100584527","phase-2-the-anti-anginal-effects-of-n-acetylcysteine-nac-in-patients-with-angina-and-non-obstructive-coronary-arteries-anoca-100584527","NCT06890507","The Anti-Anginal Effects of N-Acetylcysteine (NAC) in Patients with Angina and Non-Obstructive Coronary Arteries (ANOCA)","NANA","Inclusion Criteria:\n\n1. Provision of informed consent prior to any study specific procedures\n2. Female patients aged ≥18 years\n3. No obstructive CAD (defined as either absence of epicardial lesions with ≥50% luminal narrowing in any coronary artery segment on coronary angiography or normal findings on computed tomography (CT) angiogram, indicating the absence of significant stenosis) to account for chest pain symptoms.\n4. Chest pain occurring ≥3 times\u002Fweek in the preceding two weeks.\n\nExclusion Criteria:\n\n1. Known allergy to NAC or its components.\n2. Acute myocardial infarction admission within the preceding month (hospital admission for prolonged angina paint associated with a cardiac troponin level above the 99th percentile, with a subsequent rise or fall).\n3. Secondary causes of angina including:\n\ni. clinically significant anaemia (haemoglobin \\\u003C100g\u002FdL) ii. uncontrolled atrial fibrillation (ventricular response rate \\>108bpm) iii. haemodynamically significant aortic stenosis (mean valve gradient ≥40mmHg) d) Known concomitant disease with life expectance of less than 1 year. e) Abnormalities in liver function tests suggesting hepatic impairment (ALT and\u002For AST 2 x upper limit of normal (ULN) or ALP 2 x ULN or Bilirubin 1.5 x ULN) f) Severe renal impairment (eGFR \\\u003C30mL\u002Fmin) or on dialysis. g) Pregnancy or lactation. h) Untreated hypertension i) Unwilling, or unable, to give informed consent, including due to severe psychiatric conditions affecting informed consent process or compliance.\n\nj) History of substance abuse. k) Currently taking Chloroquine. l) Serious or unstable medical conditions that may interfere with the study, as determined by the PI.\n\nm) Concomitant participation in another clinical trial or research study (except where in the opinion of the PI, the participant could benefit from enrolling in another trial)","FEMALE",{"count":50,"type":20},25,[52],"PHASE2","The goal of this clinical trial is to determine if N-acetylcysteine (NAC) can reduce angina frequency in women with Angina with Non-Obstructive Coronary Arteries (ANOCA). It will also assess the impact of NAC on health status and quality of life. The main questions it aims to answer are:\n\n(i) Does NAC reduce the number of angina episodes per week? (ii) How does NAC affect quality of life and symptom burden in ANOCA patients? (iii) Does NAC reduce the need for short-acting nitrate use?\n\nResearchers will compare NAC to a placebo in a randomized, double-blind, placebo-controlled crossover study to determine its effectiveness.\n\nParticipants will receive treatment with NAC 600mg twice daily for 4 weeks (28 days) and matched placebo for 4 weeks (28 days) in a computer-generated random order giving a total dosing period of 8 weeks. There will be a 2-week washout between the two treatment periods.\n\nThe effectiveness of N-Acetylcysteine (NAC) will be assessed using the following measures:\n\nAngina Diary: Participants will record the frequency and severity of their angina episodes.\n\nSeattle Angina Questionnaire-7 (SAQ-7): Participants will complete this questionnaire to assess physical limitations, angina frequency, and quality of life.\n\nEuroQol 5-Dimension (EQ-5D) Questionnaire: Participants will rate their overall health and quality of life.",[55,56],"Angina Attacks","Non Obstructive Coronary Artery Disease",[58,59,60],"ANOCA","Angina with Non Obstructive Coronary Arteries","N-acetylcysteine","NOT_YET_RECRUITING","2025-03-16",{"date":64,"type":32},"2025-03-24",{"date":66,"type":20},"2025-06-01",{"date":68,"type":20},"2027-09-01",{"name":70,"class":39},"University of Adelaide"]